137 related articles for article (PubMed ID: 27452141)
1. Ipilimumab for relapse after allogeneic transplantation.
Baker H
Lancet Oncol; 2016 Sep; 17(9):e374. PubMed ID: 27452141
[No Abstract] [Full Text] [Related]
2. Ipilimumab prolongs survival in advanced melanoma.
Burki TK
Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
[No Abstract] [Full Text] [Related]
3. Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors.
Arangalage D; Delyon J; Lermuzeaux M; Ekpe K; Ederhy S; Pages C; Lebbé C
Ann Intern Med; 2017 Nov; 167(9):683-684. PubMed ID: 28869988
[No Abstract] [Full Text] [Related]
4. [Ipilimumab induced colitis].
Thielsen P; Svane IM
Ugeskr Laeger; 2015 Nov; 177(46):V66773. PubMed ID: 26573945
[No Abstract] [Full Text] [Related]
5. A 60-Year-Old Man With Progressive Anemia While Receiving Checkpoint Blockade Therapy for Relapsed Myelofibrosis.
Goodman AM; Rust M; Costello C; Ball ED
Oncology (Williston Park); 2017 Feb; 31(2):122-4, 126-8. PubMed ID: 28205192
[No Abstract] [Full Text] [Related]
6. Acute liver graft rejection after ipilimumab therapy.
Dueland S; Guren TK; Boberg KM; Reims HM; Grzyb K; Aamdal S; Julsrud L; Line PD
Ann Oncol; 2017 Oct; 28(10):2619-2620. PubMed ID: 28961840
[No Abstract] [Full Text] [Related]
7. [Severe ipilimumab-induced ulcerative colitis remitting after infliximab therapy and secondary switching with pembrolizumab].
Yelehe-Okouma M; Granel-Brocard F; Hudziak H; Schmutz JL; Gillet P
Therapie; 2018; 73(3):291-293. PubMed ID: 29203065
[No Abstract] [Full Text] [Related]
8. PD-1 blockade as bridge to allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series.
Casadei B; Broccoli A; Stefoni V; Pellegrini C; Marangon M; Morigi A; Nanni L; Lolli G; Carella M; Argnani L; Cavo M; Zinzani PL
Haematologica; 2019 Nov; 104(11):e521-e522. PubMed ID: 30890595
[No Abstract] [Full Text] [Related]
9. Autoimmune hypophysitis.
Ileana-Dumbrava E; Subbiah V
Lancet Oncol; 2018 Feb; 19(2):e123. PubMed ID: 29413466
[No Abstract] [Full Text] [Related]
10. Refractory autoimmune haemolytic anaemia following allogenic haematopoietic stem cell transplantation: successful treatment of rituximab.
Li X; Huang J; Zhu Z; Li N
J Int Med Res; 2019 Jul; 47(7):3320-3331. PubMed ID: 31280646
[TBL] [Abstract][Full Text] [Related]
11. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
[TBL] [Abstract][Full Text] [Related]
12. [Reconstitution kinetics of dendritic cells following allogeneic hematopoietic stem cell transplantation].
Fu HX; Zhang XH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):222-6. PubMed ID: 18315936
[TBL] [Abstract][Full Text] [Related]
13. [Acutely induced diabetes mellitus in a 63-year-old female after treatment with ipilimumab for metastatic melanoma].
Jørgensen LB; Yderstræde K
Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918779
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
15. Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases.
Pushkarevskaya A; Neuberger U; Dimitrakopoulou-Strauss A; Enk A; Hassel JC
J Immunother; 2017 Sep; 40(7):282-285. PubMed ID: 28604554
[TBL] [Abstract][Full Text] [Related]
16. Nonmyeloablative allogeneic hematopoietic cell transplantation.
Storb R; Sandmaier BM
Haematologica; 2016 May; 101(5):521-30. PubMed ID: 27132278
[TBL] [Abstract][Full Text] [Related]
17. Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Bishop MR; Alyea EP; Cairo MS; Falkenburg JH; June CH; Kröger N; Little RF; Miller JS; Pavletic SZ; Porter D; Riddell SR; van Besien K; Wayne AS; Weisdorf DJ; Wu R; Giralt S
Biol Blood Marrow Transplant; 2010 May; 16(5):563-4. PubMed ID: 20202482
[No Abstract] [Full Text] [Related]
18. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
Subudhi SK; Aparicio A; Gao J; Zurita AJ; Araujo JC; Logothetis CJ; Tahir SA; Korivi BR; Slack RS; Vence L; Emerson RO; Yusko E; Vignali M; Robins HS; Sun J; Allison JP; Sharma P
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):11919-11924. PubMed ID: 27698113
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
[TBL] [Abstract][Full Text] [Related]
20. Bilateral ipilimumab-induced posterior uveitis following treatment for metastatic choroidal melanoma.
Tan AX; Ang A; Campbell WG; Fabinyi DC
Clin Exp Ophthalmol; 2018 Sep; 46(7):819-821. PubMed ID: 29653019
[No Abstract] [Full Text] [Related]
[Next] [New Search]
